A Study to Investigate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 Administered IM in Adult Participants
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05762276 |
Recruitment Status :
Active, not recruiting
First Posted : March 9, 2023
Last Update Posted : October 12, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hypercholesterolemia | Drug: VXX-401 Biological: Placebo | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 64 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Masking Description: | Cohorts A-D are blinded / Cohort E & F are open label |
Primary Purpose: | Treatment |
Official Title: | A Phase 1, First-in-Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 in Healthy Adults |
Actual Study Start Date : | March 7, 2023 |
Estimated Primary Completion Date : | June 27, 2024 |
Estimated Study Completion Date : | June 27, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: VXX-401 Cohort A
VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
|
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy |
Experimental: VXX-401 Cohort B
VXX-401 100mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
|
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy |
Experimental: VXX-401 Cohort C
VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
|
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy |
Experimental: VXX-401 Cohort D
VXX-401 300mcg administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
|
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy |
Placebo Comparator: Placebo Cohort A and C
Placebo administered by intramuscular (IM) injection at Week 0, Week 4, and Week 12
|
Biological: Placebo
Normal saline |
Placebo Comparator: Placebo Cohort B and D
Placebo administered by intramuscular (IM) injection at Week 0, Week 4, Week 8 and Week 12
|
Biological: Placebo
Normal saline |
Experimental: VXX-401 Cohort E
VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 100 mcg administered by intramuscular (IM) injection at Week 4 and Week 12.
|
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy |
Experimental: VXX-401 Cohort F
VXX-401 900mcg administered by intramuscular (IM) injection at Week 0. VXX-401 300 mcg administered by intramuscular (IM) injection at Week 4 and Week 12.
|
Drug: VXX-401
A synthetic PCSK9 peptide-based immunotherapy |
- Frequency of adverse events [ Time Frame: 30 weeks ]Safety and tolerability: rates of adverse events (AEs), medically attended adverse events (MAAEs), local (injection site) and systemic (generalized) reactions (i.e., reactogenicity), clinical laboratory assessments (e.g., chemistry, hematology, urinalysis, lipid profile), serum cytokine release, vital signs, physical examinations, and electrocardiograms (ECGs) through the end of the study.
- Immunogenicity [ Time Frame: Baseline to Week 16, 20, 24, and 30 ]Immunogenicity will be measured by serum anti-PCSK9 antibody titers
- Immunogenicity [ Time Frame: Baseline to Week 16, 20, 24, and 30 ]Seroconversion two-fold and four-fold from baseline
- Determine optimal VXX-401 dose regimen [ Time Frame: Baseline to Week 16, 20, 24, and 30 ]Measured by serum anti-PCSK9 antibody titers
- Evaluation of low-density lipoprotein-cholesterol (LDL-C) reduction [ Time Frame: Baseline to Week 16, 20, 24, and 30 ]Percent change from baseline in serum LDL-C concentration
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Male or female participants aged 18 to 75 years old, inclusive, at time of informed consent.
- LDL-C level = 2.59 mmol/L - 4.89mmol/L
- Body mass index between 18 and 35 kg/m2, inclusive at Screening, and with a minimum weight of 50 kg.
- Male participants and their partners of childbearing potential must commit to the use of highly effective contraceptives for the study duration and for at least 12 weeks after the last dose. Men must refrain from donating sperm during this same period.
- Female participants must be of nonchildbearing potential, or, for women of childbearing potential, must be willing to practice at least one form of highly effective contraception throughout the duration of the study and for at least 24 weeks following the last dose. Female participants must refrain from donating reproductive tissue during this same period.
Exclusion Criteria:
- Subjects considered high risk or very high risk for ASCVD and requiring immediate treatment with LLT according to the clinical judgement of the investigator.
- History of confirmed anergy (i.e., not able to mount an immunological response) or history of immunization failure in the 5 years prior to the Screening Visit.
- Presence of fever >38°C or other signs or symptoms of acute disease within 1 week before the Screening and/or Visit 1; Screening and/or Visit 1 may be rescheduled at the discretion of the Investigator but must occur within the 4-week window.
- Known disturbance of coagulation or medication (see prohibited medications criterion below); bleeding disorder (e.g., factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following IM injections or venipuncture.
- Triglycerides > 5.65 mmol/L
- Has a history of clinically significant medical disorder or psychiatric conditions, which in the opinion of the investigator may compromise the participant's safety and ability to comply with study procedures or abide by study restrictions.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05762276
Australia, New South Wales | |
Northern Beaches Clinical Research | |
Brookvale, New South Wales, Australia | |
Sutherland Shire Clinical Research | |
Miranda, New South Wales, Australia | |
Emeritus Research | |
Sydney, New South Wales, Australia | |
Australia, Queensland | |
University of the Sunshine Coast (USC) | |
Morayfield, Queensland, Australia | |
Australia, Victoria | |
Emeritus Research | |
Melbourne, Victoria, Australia |
Study Director: | Sasha Rumyantsev | Vaxxinity, Inc. |
Responsible Party: | Vaxxinity, Inc. |
ClinicalTrials.gov Identifier: | NCT05762276 |
Other Study ID Numbers: |
VXX-401-101 |
First Posted: | March 9, 2023 Key Record Dates |
Last Update Posted: | October 12, 2023 |
Last Verified: | October 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Hypercholesterolemia Hyperlipidemias Dyslipidemias Lipid Metabolism Disorders Metabolic Diseases |